Hydrochlorothiazide: A savior to the heart or a foe to the skin?

Kumar, Ayush; Priya, .; Khatri, Govinda; Swed, Sarya; Hasan, Mohammad Mehedi

doi:10.1016/j.amsu.2022.103954

Cited by 1 publication

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, our WCE estimates suggest that NMSC incidence may increase about 2.5–4 years after initiation of a continuous HCTZ use. However, clinical decision‐making must carefully consider the risk–benefit ratio of a potential increase of NMSC risk with HCTZ 49,50 as well as potential photosensitizing/carcinogenic effects of other antihypertensive drugs, including angiotensin‐converting enzyme inhibitors 51 …”

Section: Discussionmentioning

confidence: 99%

“…Specifically, our WCE estimates suggest that NMSC incidence may increase about 2.5-4 years after initiation of a continuous HCTZ use. However, clinical decisionmaking must carefully consider the risk-benefit ratio of a potential increase of NMSC risk with HCTZ 49,50 as well as potential photosensitizing/carcinogenic effects of other antihypertensive drugs, including angiotensin-converting enzyme inhibitors. 51 Overall, our flexible WCE analyses helped address some analytical and conceptual challenges in pharmacoepidemiological studies of potential carcinogenic drug effects, highlighted by other authors.…”

Section: Rowmentioning

confidence: 99%

See 1 more Smart Citation

Importance of accounting for timing of time‐varying exposures in association studies: Hydrochlorothiazide and non‐melanoma skin cancer

Danieli,

Moura,

Pilote

et al. 2023

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

PurposeHydrochlorothiazide (HCTZ), a widely prescribed antihypertensive drug with photosensitising properties, has been linked with non‐melanoma skin cancer (NMSC) risk. However, previous analyses did not fully explore if and how the impact of past HCTZ exposures accumulates with prolonged use and/or depends on time elapsed since exposures. Therefore, we used different models to more comprehensively assess how NMSC risk vary with HCTZ exposure, and explore how the results may depend on modeling strategies.MethodsWe used different parametric models with alternative time‐varying exposure metrics, and the flexible weighted cumulative exposure model (WCE) to estimate associations between HCTZ exposures and NMSC risk in a population‐based cohort of HCTZ users over 65 years old, in the province of Ontario, Canada.ResultsAmong 3844 HCTZ users, 273 developed NMSC during up to 8 years of follow‐up. In parametric models, based on all exposures, increased duration of past HCTZ use was associated with an increase of NMSC risk but cumulative dose showed no systematic association. Yet, WCE results suggested that only exposures taken 2.5–4 years in the past were associated with the current NMSC hazard. This finding led us to re‐define the parametric models, which also confirmed that any HCTZ dose taken outside this time‐window were not systematically associated with NMSC incidence.ConclusionsOur analyses illustrate how flexible modeling may yield new insights into complex temporal relationships between a time‐varying drug exposure and risks of adverse events. Duration and recency of antihypertensive agents exposures must be taken into account in evaluating risk and benefits.

show abstract

Section: Discussionmentioning

confidence: 99%